Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.
David S. Khoury,Deborah Cromer,Arnold Reynaldi,Timothy E. Schlub,Timothy E. Schlub,Adam K. Wheatley,Jennifer A Juno,Kanta Subbarao,Stephen J. Kent,Stephen J. Kent,Stephen J. Kent,James A. Triccas,Miles P. Davenport +12 more
TLDR
It is shown that neutralization level is highly predictive of immune protection, and an evidence-based model of SARS-CoV-2 immune protection that will assist in developing vaccine strategies to control the future trajectory of the pandemic is provided.Abstract:
Predictive models of immune protection from COVID-19 are urgently needed to identify correlates of protection to assist in the future deployment of vaccines. To address this, we analyzed the relationship between in vitro neutralization levels and the observed protection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection using data from seven current vaccines and from convalescent cohorts. We estimated the neutralization level for 50% protection against detectable SARS-CoV-2 infection to be 20.2% of the mean convalescent level (95% confidence interval (CI) = 14.4–28.4%). The estimated neutralization level required for 50% protection from severe infection was significantly lower (3% of the mean convalescent level; 95% CI = 0.7–13%, P = 0.0004). Modeling of the decay of the neutralization titer over the first 250 d after immunization predicts that a significant loss in protection from SARS-CoV-2 infection will occur, although protection from severe disease should be largely retained. Neutralization titers against some SARS-CoV-2 variants of concern are reduced compared with the vaccine strain, and our model predicts the relationship between neutralization and efficacy against viral variants. Here, we show that neutralization level is highly predictive of immune protection, and provide an evidence-based model of SARS-CoV-2 immune protection that will assist in developing vaccine strategies to control the future trajectory of the pandemic. Estimates of the levels of neutralizing antibodies necessary for protection against symptomatic SARS-CoV-2 or severe COVID-19 are a fraction of the mean level in convalescent serum and will be useful in guiding vaccine rollouts.read more
Citations
More filters
Journal ArticleDOI
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.
Delphine Planas,David Veyer,Artem Baidaliuk,Isabelle Staropoli,Florence Guivel-Benhassine,Maaran Michael Rajah,Maaran Michael Rajah,Cyril Planchais,Françoise Porrot,Nicolas Robillard,Julien Puech,Matthieu Prot,Floriane Gallais,Pierre Gantner,Aurélie Velay,Julien Le Guen,Najiby Kassis-Chikhani,Dhiaeddine Edriss,Laurent Bélec,Aymeric Sève,Laura Courtellemont,Hélène Péré,Laurent Hocqueloux,Samira Fafi-Kremer,Thierry Prazuck,Hugo Mouquet,Timothée Bruel,Etienne Simon-Loriere,Félix A. Rey,Olivier Schwartz +29 more
TL;DR: In this paper, an infectious strain of the SARS-CoV-2 Delta variant was isolated from an individual with COVID-19 who had returned to France from India.
Journal ArticleDOI
Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
TL;DR: A rapid increase in coronavirus disease 2019 (Covid-19) cases due to the omicron (B.1.529) variant in highly vaccinated populations has aroused concerns about the effectiveness of current vaccines as mentioned in this paper .
Journal ArticleDOI
Covid-19 Breakthrough Infections in Vaccinated Health Care Workers.
Moriah Bergwerk,Tal Gonen,Yaniv Lustig,Sharon Amit,Marc Lipsitch,Carmit Cohen,Michal Mandelboim,Einav G Levin,Carmit Rubin,Victoria Indenbaum,Ilana Tal,Malka Zavitan,Neta S. Zuckerman,Adina Bar-Chaim,Yitshak Kreiss,Gili Regev-Yochay +15 more
TL;DR: Despite the high efficacy of the BNT162b2 messenger RNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), rare breakthrough infections have been reported.
Journal ArticleDOI
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study.
Sara Y. Tartof,Jeff Slezak,Heidi Fischer,Vennis Hong,Bradley Ackerson,Omesh N. Ranasinghe,Timothy B. Frankland,Oluwaseye A. Ogun,Joann M. Zamparo,Sharon Gray,Srinivas Rao Valluri,Kaije Pan,Frederick J. Angulo,Luis Jodar,John M McLaughlin +14 more
TL;DR: In this paper, the overall and variant-specific effectiveness of BNT162b2 (tozinameran, Pfizer BioNTech) against SARS-CoV-2 infections and COVID-19-related hospital admissions by time since vaccination among members of a large US health-care system was evaluated.
Journal ArticleDOI
mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant
Wilfredo F. Garcia-Beltran,K. S. St. Denis,Angelique Hoelzemer,Evan C. Lam,Adam Nitido,M. Sheehan,Cristhian Berríos,Onosereme Ofoman,Christina C. Chang,Blake M. Hauser,Jared Feldman,Alex Roederer,David Gregory,Mark C. Poznansky,Aaron G. Schmidt,A. John Iafrate,Vivek Naranbhai,Alejandro B. Balazs +17 more
TL;DR: In this article , the authors measured the neutralization potency of sera from 88 mRNA-1273, 111 BNT162b, and 40 Ad26.1.1/B.COV2.
References
More filters
Journal ArticleDOI
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.
Alicia T. Widge,Nadine Rouphael,Lisa A. Jackson,Evan J. Anderson,Paul C. Roberts,Mamodikoe Makhene,James D. Chappell,Mark R. Denison,Laura J. Stevens,Andrea J. Pruijssers,Adrian B. McDermott,Britta Flach,Bob C. Lin,Nicole A. Doria-Rose,Sijy O'Dell,Stephen D. Schmidt,Kathleen M. Neuzil,Hamilton Bennett,Brett Leav,Mat Makowski,Jim Albert,Kaitlyn Cross,Venkata Viswanadh Edara,Katharine Floyd,Mehul S. Suthar,Wendy Buchanan,Catherine J. Luke,Julie E. Ledgerwood,John R. Mascola,Barney S. Graham,John H. Beigel +30 more
TL;DR: A small number of adults received two 100-μg injections of Moderna’s mRNA SARS-CoV-2 vaccine, and serum anti–spike protein and neutralizing antibody titers revealed immunogenicity and safety concerns.
Journal ArticleDOI
The Time Course of the Immune Response to Experimental Coronavirus Infection of Man
TL;DR: A limited investigation of circulating lymphocyte populations showed some lymphocytopenia in infected volunteers and antibody concentrations started to increase 1 week after inoculation and reached a maximum about 1 week later, thereafter antibody titres slowly declined.
Journal ArticleDOI
Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19.
Lauren B. Rodda,Jason Netland,Laila Shehata,Kurt B Pruner,Peter A. Morawski,Christopher D. Thouvenel,Kennidy K Takehara,Julie Eggenberger,Emily A. Hemann,Hayley R Waterman,Mitchell L Fahning,Yu Chen,Yu Chen,Malika Hale,Malika Hale,Jennifer A Rathe,Caleb Stokes,Samuel Wrenn,Brooke Fiala,Lauren Carter,Jessica A. Hamerman,Neil P. King,Michael Gale,Daniel J. Campbell,Daniel J. Campbell,David J. Rawlings,Marion Pepper +26 more
TL;DR: Mild COVID-19 elicits memory lymphocytes that persist and display functional hallmarks of antiviral immunity, and SARS-CoV-2-specific memory lymphocyte exhibited characteristics associated with potent antiviral function.
Journal ArticleDOI
Neutralizing Activity of BNT162b2-Elicited Serum.
Yang Liu,Jianying Liu,Hongjie Xia,Xianwen Zhang,Camila R. Fontes-Garfias,Kena A. Swanson,Hui Cai,Ritu Sarkar,Wei Chen,Mark Cutler,David A. Cooper,Scott C. Weaver,Alexander Muik,Ugur Sahin,Kathrin U. Jansen,Xuping Xie,Philip R. Dormitzer,Pei Yong Shi +17 more
TL;DR: In this paper, the BNT162b2 vaccine was shown to neutralize the P.1.1, B.1., B.7, and B.135 lineages of SARS-CoV-2.
Journal ArticleDOI
Logistic-normal distributions:Some properties and uses
J. Atchison,S.M. Shen +1 more
TL;DR: In this article, the logistic transformation applied to a 2-dimensional normal distribution produces a distribution over the d-dimensional simplex which can sensibly be termed a logistic-norma l distribution.
Related Papers (5)
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Fernando P. Polack,Stephen J. Thomas,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Edson D. Moreira,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Satrajit Roychoudhury,Kenneth Koury,Ping Li,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +28 more
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
Lindsey R. Baden,Hana M. El Sahly,Brandon Essink,Karen L. Kotloff,Sharon E. Frey,Rick Novak,David Diemert,Stephen A. Spector,Nadine Rouphael,C. Buddy Creech,John W McGettigan,Shishir Khetan,Nathan Segall,Joel Solis,Adam Brosz,Carlos Fierro,Howard J. Schwartz,Kathleen M. Neuzil,Lawrence Corey,Peter B. Gilbert,Holly Janes,Dean Follmann,Mary A. Marovich,John R. Mascola,Laura Polakowski,Julie E. Ledgerwood,Barney S. Graham,Hamilton Bennett,Rolando Pajon,Conor Knightly,Brett Leav,Weiping Deng,Honghong Zhou,Shu Liang Han,Melanie Ivarsson,Jacqueline Miller,Tal Z Zaks +36 more
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Jennifer M. Dan,Jennifer M. Dan,Jose Mateus,Yu Kato,Kathryn M. Hastie,Esther Dawen Yu,Caterina E. Faliti,Alba Grifoni,Sydney I. Ramirez,Sydney I. Ramirez,Sonya Haupt,April Frazier,Catherine Nakao,Vamseedhar Rayaprolu,Stephen A. Rawlings,Bjoern Peters,Bjoern Peters,Florian Krammer,Viviana Simon,Erica Ollmann Saphire,Erica Ollmann Saphire,Davey M. Smith,Daniela Weiskopf,Alessandro Sette,Alessandro Sette,Shane Crotty,Shane Crotty +26 more
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Merryn Voysey,Clemens Sac.,Shabir A. Madhi,Lily Yin Weckx,P M Folegatti,Parvinder K. Aley,Brian Angus,Vicky L. Baillie,Shaun Barnabas,Q E Bhorat,S Bibi,Carmen Briner,P Cicconi,Andrea M. Collins,R Colin-Jones,Clare L. Cutland,Thomas C. Darton,Keertan Dheda,Duncan Cja.,Emary Krw.,Katie J. Ewer,Lee Fairlie,Saul N. Faust,Shuo Feng,Daniela M. Ferreira,Adam Finn,Anna Goodman,Catherine M. Green,Christopher A Green,Paul T. Heath,Christopher Hill,Helen Hill,Ian Hirsch,Hodgson Shc.,Allen Izu,S Jackson,D Jenkin,Joe Ccd.,S Kerridge,Anthonet Koen,Gaurav Kwatra,Rajeka Lazarus,Alison M. Lawrie,A Lelliott,Vincenzo Libri,Patrick J. Lillie,R Mallory,Mendes Ava.,Eveline Pipolo Milan,Angela M. Minassian,Alastair McGregor,Hazel Morrison,Y Mujadidi,Amit J Nana,P J O’Reilly,S D Padayachee,A Pittella,E Plested,Katrina M Pollock,M N Ramasamy,S Rhead,Alexandre Vargas Schwarzbold,Nisha Singh,Andrew Smith,R Song,Matthew D. Snape,Eduardo Sprinz,Rebecca K. Sutherland,R Tarrant,E. Thomson,M E Török,Mark Toshner,Turner Dpj.,Johan Vekemans,Tonya Villafana,Watson Mee.,C J Williams,Alexander D. Douglas,Hill Avs.,Teresa Lambe,Sarah C. Gilbert,Andrew J. Pollard +81 more